基于胰岛素的肝病疗法

IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Eleni Kotsiliti
{"title":"基于胰岛素的肝病疗法","authors":"Eleni Kotsiliti","doi":"10.1038/s41575-024-00961-w","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 8","pages":"533-533"},"PeriodicalIF":45.9000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incretin-based therapies for liver disease\",\"authors\":\"Eleni Kotsiliti\",\"doi\":\"10.1038/s41575-024-00961-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18793,\"journal\":{\"name\":\"Nature Reviews Gastroenterology &Hepatology\",\"volume\":\"21 8\",\"pages\":\"533-533\"},\"PeriodicalIF\":45.9000,\"publicationDate\":\"2024-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Gastroenterology &Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41575-024-00961-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Gastroenterology &Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41575-024-00961-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

6月初,欧洲肝脏研究协会(European Association for the Study of the Liver)召开了2024年大会(6月5-8日),与此同时,四项评估增量素类药物在脂肪性肝病和肝硬化中疗效和安全性的试验也相继公布。在一项II期、剂量调查、多中心、双盲临床试验(SYNERGY-NASH)中,Rohit Loomba及其同事对190名经活检确诊为MASH和F2或F3期肝脏纤维化的患者使用替扎帕肽(一种双重葡萄糖依赖性促胰岛素多肽(GIP)-GLP1受体激动剂)的安全性和有效性进行了评估。受试者被随机分配到每周一次皮下注射 5 毫克、10 毫克或 15 毫克剂量的替哌肽或安慰剂,为期 52 周。5毫克组有44%的患者(95% CI为17-50)、10毫克组有56%的患者(95% CI为29-62)、15毫克组有62%的患者(95% CI为37-69)达到了MASH缓解且纤维化不恶化(主要终点)的要求(与安慰剂相比,三组的P< 0.001),而安慰剂组只有10%的患者达到了这一要求。次要终点也达到了要求,包括55%的5毫克组患者(95% CI 5-46)、51%的10毫克组和15毫克组患者(95% CI 1-42)纤维化改善≥1期,而安慰剂组为30%。最常见的不良反应是轻度至中度胃肠道事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Incretin-based therapies for liver disease

Incretin-based therapies for liver disease
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
52.30
自引率
0.60%
发文量
147
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信